organization · Reporting owner
Puissance Life Science Opportunities Fund VI
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tracon Pharmaceuticals, Inc.TCON · Entity 91134 | 10% owner | November 29, 2018 | December 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tracon Pharmaceuticals, Inc.
Report date November 29, 2018 · Filed December 03, 2018 · Amendment
Jointly reported with Puissance Cross-Border Opportunities V LLC, Puissance Cross-Border Opportunities IV LLC, Puissance Capital Management LP, Puissance Capital Management (GP) LLC, Puissance Capital Fund (GP) LLC, Wang Theodore T
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,606,094 |
Reported balance
After 2018-11-29 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-11-29 · Purchase · Acquired 4,326 · Balance 4,606,094 F4: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,601,768 |
Reported balance
After 2018-11-29 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2018-11-29 · Sale · Disposed 4,326 · Balance 4,601,768 F4: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,601,768 |
Reported balance
Holding disclosure · report date 2018-11-29 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 4,601,768 F1: Consists of: 2,831,857 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Shares directly owned Puissance Cross-Border Opportunities IV LLC. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2024-03-27 | IndirectBy funds | 4,601,768 |
Reported balance
Holding disclosure · report date 2018-11-29 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 4,601,768 F2: Consists of: 2,831,857 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Warrants directly owned Puissance Cross-Border Opportunities IV LLC. F3: Puissance Capital Fund (GP) LLC serves as the managing member of Puissance Cross-Border Opportunities V LLC, Puissance Life Science Opportunities Fund VI and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management LP serves as the investment manager of Puissance Cross-Border Opportunities V LLC, Puissance Life Science Opportunities Fund VI and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management (GP) LLC serves as the general partner to Puissance Capital Management LP and may be deemed to beneficially own these shares. Theodore T. Wang serves as the managing member of Puissance Capital Fund (GP) LLC and Puissance Capital Management (GP) LLC and may be deemed to beneficially own these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of: 2,831,857 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Shares directly owned Puissance Cross-Border Opportunities IV LLC.
F2: Consists of: 2,831,857 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 1,769,911 Warrants directly owned Puissance Cross-Border Opportunities IV LLC.
F3: Puissance Capital Fund (GP) LLC serves as the managing member of Puissance Cross-Border Opportunities V LLC, Puissance Life Science Opportunities Fund VI and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management LP serves as the investment manager of Puissance Cross-Border Opportunities V LLC, Puissance Life Science Opportunities Fund VI and Puissance Cross-Border Opportunities IV LLC and may be deemed to beneficially own these shares. Puissance Capital Management (GP) LLC serves as the general partner to Puissance Capital Management LP and may be deemed to beneficially own these shares. Theodore T. Wang serves as the managing member of Puissance Capital Fund (GP) LLC and Puissance Capital Management (GP) LLC and may be deemed to beneficially own these shares.
F4: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bellerophon Therapeutics, Inc.
Report date October 13, 2023 · Filed October 16, 2023
Jointly reported with Puissance Capital Management LP, Puissance Capital Fund (GP) LLC, Wang Theodore T
Section 16 reporting ended · disclosed 2023-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-13 · Sale · Disposed 1,076,841 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2023 Filed Oct 16, 2023 20:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 1,076,841 | $0.10 | $111,776.10 |
DisclosureSEC source: 0001760460-23-000008 · primary_doc.xml · nonDerivative · entry 1 Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:21 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 134,421 | $0.83 | $111,569.43 |
DisclosureSEC source: 0001760460-23-000006 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,841 Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:55 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 560,000 | $9.46 | $5,297,600.00 |
DisclosureSEC source: 0001760460-23-000003 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,211,262 Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 12:37 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 8,189 | $4.00 | $32,756.00 |
DisclosureSEC source: 0001760460-21-000004 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,262 F1 · ownership.direct: 1. These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 304,286 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 3 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,236 Underlying: Common Stock · 304,286 shares Expires 2022-09-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 380,950 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 2 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,950 Underlying: Common Stock · 380,950 shares Expires 2023-11-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 609,231 | $4.00 | $2,436,924.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,077 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 21, 2020 Filed May 22, 2020 07:25 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 1,153,846 | $13.00 | $14,999,998.00 |
DisclosureSEC source: 0001760460-20-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153,846 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.